Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $4.0 million.

  • ImmunityBio's Depreciation & Amortization (CF) fell 1131.31% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 1213.57%. This contributed to the annual value of $17.6 million for FY2024, which is 517.5% down from last year.
  • Per ImmunityBio's latest filing, its Depreciation & Amortization (CF) stood at $4.0 million for Q3 2025, which was down 1131.31% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Depreciation & Amortization (CF) registered a high of $5.2 million during Q4 2022, and its lowest value of $3.0 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $4.4 million (2024), whereas its average is $4.2 million.
  • As far as peak fluctuations go, ImmunityBio's Depreciation & Amortization (CF) surged by 6150.04% in 2021, and later crashed by 1593.85% in 2025.
  • ImmunityBio's Depreciation & Amortization (CF) (Quarter) stood at $3.6 million in 2021, then soared by 45.37% to $5.2 million in 2022, then fell by 12.67% to $4.6 million in 2023, then fell by 9.33% to $4.1 million in 2024, then dropped by 4.52% to $4.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $4.0 million for Q3 2025, versus $3.9 million for Q2 2025 and $3.8 million for Q1 2025.